Page 82 - Read Online

Malentacchi et al. J Cancer Metastasis Treat 2020;6:34 I http://dx.doi.org/10.20517/2394-4722.2020.34 Page 15 of 18

6. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet 2016;387:1094-108.
7. McGuire S. World cancer report 2014. Geneva, Switzerland: world Health organization, international Agency for research on cancer,
WHO press. Adv Nutr 2015;7:418-9.
8. Bockman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-7.
9. Levine DA. The Cancer Genome Atlas Research Network Integrated genomic characterization of endometrial carcinoma. Nature
2013;497:67-73.
10. Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, et al; ESMO-ESGO-ESTRO Endometrial Consensus Conference
Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol
2016;27:16-41.
11. Ruz-Caracuel I, Ramón-Patino JL, López-Janeiro Á, Yébenes L, Berjón A, et al. Pattern as a prognostic marker in low-grade, early-stage
endometrioid endometrial carcinoma. Cancers 2019;11:e1845.
12. Marius Ilié M and Hofman P. Pros: Can tissue biopsy be replaced by liquid biopsy? Transl Lung Cancer Res 2016;5:420-3.
13. García-Foncillas J, Tabernero J, Elena Élez E, Enrique Aranda E, Benavides M, et al. Prospective multicenter real-world RAS mutation
comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. Br J Cancer 2018;119:1464-70.
14. Bidard FC, Kiavue N, Ychou M, Cabel L, Stern MH, et al. Circulating tumor cells and circulating tumor DNA detection in potentially
resectable metastatic colorectal cancer: a prospective ancillary study to the unicancer. Prodige-14 Trial. Cells 2019;8:516.
15. Tuaeva NO, Falzone L, Porozov YB, Nosyrev AE, Trukhan VM, et al. Translational application of circulating DNA in oncology: review
of the last decades achievements. Cells 2019;8:1251.
16. Mayo-de-Las-Casas C, Velasco A, Sanchez D, Martínez-Bueno A, Garzón-Ibáñez M, et al. Detection of somatic mutations in peritoneal
lavages and plasma of endometrial cancer patients: a proof-of-concept study cancer. Int J Cancer 2020;147:277-84.
17. Mego M, Cholujova D, Minarik G, Sedlackova T, Gronesova P, et al. CXCR4-SDF-1 interaction potentially mediates trafficking of
circulating tumor cells in primary breast cancer. BMC Cancer 2016;16:127.
18. Liu Q, Liao Q, Zhao Y. Myeloid-derived suppressor cells (MDSC) facilitate distant metastasis of malignancies by shielding circulating
tumor cells (CTC) from immune surveillance. Medical Hypotheses 2016;87:34-9.
19. Kloten V, Lampignano R, Krahn T, Schlange T. Circulating tumor cell PD-L1 expression as biomarker for therapeutic efficacy of immune
checkpoint inhibition in NSCL. Cells 2019;8:e809.
20. Sharma S, Zhuang R, Long M, Pavlovic M, Kang Y, et al. Circulating tumor cell isolation, culture, and downstream molecular analysis.
Biotechnol Adv 2018;36:1063-78.
21. Bankó P, Lee SY, Nagygyörgy V, Zrínyi M, Chae CH, et al. Technologies for circulating tumor cell separation from whole blood. J
Hematol Oncol 2019;12:48.
22. Alonso-Alconada L, Muinelo-Romay L, Madissoo K, Diaz-Lopez A, Krakstad C, et al. Molecular profiling of circulating tumor cells
links plasticity to the metastatic process in endometrial cancer. Molecular Cancer 2014;13:223.
23. Masuda T, Hayashi N, Iguchi T, Ito S, Eguchi H, et al. Clinical and biological significance of circulating tumor cells in cancer. Mol Oncol
2016;10:e408-e417
24. Muinelo-Romay L, Casas-Arozamena C, Abal M. Liquid biopsy in endometrial cancer: new opportunities for personalized oncology. Int
J Mol Sci 2018;19:2311.
25. Pixberg CF, Schulz WA, Stoecklein NH, Neves RPL. Characterization of DNA methylation in circulating tumor cells. Genes
2015;6:1053-75.
26. Zhang Y, Qu X, Qu PP. Value of circulating tumor cells positive for thyroid transcription factor-1 (TTF-1) to predict recurrence and
survival rates for endometrial carcinoma. J BUON 2016;21:1491-5.
27. Kolbl AC, Wellens R, Koch J, Rack B, Hutter S, et al. Endometrial adenocarcinoma: analysis of circulating tumour cells by RT-qPCR.
Anticancer Res 2016;36:3205-10.
28. Bao H, Burke PA, Huang J, Chen X, Brohawn PZ, et al. Circulating tumor cells: application as a biomarker for molecular characterization
and predictor of survival in an all-comer solid tumor phase I clinical study. PLoSOne2013;8:e58557.
29. Kiss I, Kolostova K, Matkowski R, Jędryka M, Czekański A, et al. Correlation between disease stage and the presence of viable
circulating tumorcells in endometrial cancer. Anticancer Res 2018;38:2983-7.
30. Bogani G, Liu MC, Dowdy SC, Cliby WA, Kerr SE, et al. Detection of circulating tumor cells in high-risk endometrial cancer. Anticancer
Res 2015;35:683-8.
31. Walter CB, Taran FA, Wallwiener M, Rothmund R, Kraemer B, et al. Prevalence and prognostic value of disseminated tumor cells in
primary endometrial, cervical and vulvar cancer patients. Future Oncol 2014;10:41-8.
32. Obermayr E, Sanchez-Cabo F, Tea MKM, Singer CF, Krainer M, et al. Assessment of a six gene panel for the molecular detection of
circulating tumor cells in the blood of female cancer patients. BMC Cancer 2010;10:666.
33. Zou J, Wang E. eTumorType, an algorithm of discriminating cancer types for circulating tumor cells or cell-free DNAs in blood. Gen Prot
Bioinformatics 2017;15:130-40.
34. Kolostova K, Spicka J, Matkowski R, Bobek V. Isolation, primary culture, morphological and molecular characterization of circulating
tumor cells in gynecological cancers. Am J Transl Res 2015;7:1203-13.
35. Lim SB, Lee WD, Vasudevan J, Lim WT, Lim CT. Liquid biopsy: one cell at a time NPJ Precis Oncol 2019;3:23.
36. Snyder A, Morrissey MP, Hellmann MD. Use of circulating tumor DNA for cancer immunotherapy. Clin Cancer Res 2019;25:6909-15.
37. Pereira E, Camacho-Vanegas O, Anand S, Sebra R, Camacho SC, et al. Personalized circulating tumor DNA biomarkers dynamically
predict treatment response and survival in gynecologic cancers. PLoS One 2015;10:e0145754.